Sofpironium bromide is a structural analogue of glycopyrrolate, an anticholinergic agent. Positive topline results were announced from 2 identical phase 3 studies evaluating sofpironium bromide in ...

BOULDER, Colo., May 03, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (Nasdaq: BBI) (“Brickell” or “Company”), a clinical-stage pharmaceutical company striving to transform patient lives by ...

Please provide your email address to receive an email when new articles are posted on . Sofpironium bromide gel reduced hyperhidrosis with few adverse events in Japanese patients, according to ...

SAN DIEGO--(BUSINESS WIRE)--Brickell Biotech, Inc. (“Brickell”), a clinical-stage medical dermatology company, today announced that the positive confirmatory Phase 2b study (CL-203) results with ...

Sofpironium bromide in the treatment of primary axillary hyperhidrosis improves Hyperhidrosis Disease Severity Scale scores, reduces gravimetric weight of sweat, and improves Dermatology Life Quality ...

BOULDER, Colo., Sept. 25, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated ...

BOULDER, Colo.--(BUSINESS WIRE)--Brickell Biotech, Inc. (“Brickell”), a clinical-stage medical dermatology company, today announced positive results of its confirmatory Phase 2b study of sofpironium ...

Please provide your email address to receive an email when new articles are posted on . Treatment with sofpironium bromide gel reduced the severity of primary axillary hyperhidrosis in a cohort of ...

BOULDER, Colo., June 15, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated ...

Colorado-based Brickell, which focuses on developing therapeutics for the treatment of debilitating skin diseases, announced publication in the Journal of the American Academy of Dermatology positive ...

BOULDER, Colo., Sept. 25, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated ...

Japan is the first country to approve sofpironium bromide with commerciallaunch expected later this year Brickell is on track to initiate its U.S. pivotal Phase 3 program for sofpironium bromide in Q4 ...